Insurance Coverage: Semaglutide vs Tirzepatide

The short answer

Coverage follows indications, not molecules. Where the two diverge on approved uses.

Across the 14 programmes in our dataset carrying both molecules, tirzepatide runs consistently higher than semaglutide at the same platform. The cheapest semaglutide programme we track is Mochi Health at $99 a month; the cheapest tirzepatide is NexLife at $215 a month all-in at a 10 mg maintenance dose. Prices captured 2026-08-05.

Both molecules, same platform, written out

Comparing across platforms confuses the molecule difference with the platform difference. These are the programmes carrying both, so the gap is the molecule.

Mochi Health charges $178 a month for semaglutide and $278 for tirzepatide at a 10 mg maintenance dose, a difference of $100 a month, or $1,200 across a year. Both are billed on the same flat structure. Captured 2026-08-05.

MEDVi charges $134 a month for semaglutide and $399 for tirzepatide at a 10 mg maintenance dose, a difference of $265 a month, or $3,180 across a year. Both are billed on the same flat structure. Captured 2026-08-05.

NexLife charges $145 a month for semaglutide and $215 for tirzepatide at a 10 mg maintenance dose, a difference of $70 a month, or $840 across a year. Both are billed on the same flat structure. Captured 2026-08-05.

Yucca Health charges $146 a month for semaglutide and $258 for tirzepatide at a 10 mg maintenance dose, a difference of $112 a month, or $1,344 across a year. Both are billed on the same flat structure. Captured 2026-08-05.

Henry Meds charges $149 a month for semaglutide and $349 for tirzepatide at a 10 mg maintenance dose, a difference of $200 a month, or $2,400 across a year. Both are billed on the same flat structure. Captured 2026-08-05.

IVIM Health charges $224 a month for semaglutide and $278 for tirzepatide at a 10 mg maintenance dose, a difference of $54 a month, or $648 across a year. Both are billed on the same scaled structure. Captured 2026-08-05.

Lavender Sky Health charges $174 a month for semaglutide and $352 for tirzepatide at a 10 mg maintenance dose, a difference of $178 a month, or $2,136 across a year. Both are billed on the same scaled structure. Captured 2026-08-05.

Eden charges $278 a month for semaglutide and $408 for tirzepatide at a 10 mg maintenance dose, a difference of $130 a month, or $1,560 across a year. Both are billed on the same scaled structure. Captured 2026-08-05.

TrimRx charges $199 a month for semaglutide and $349 for tirzepatide at a 10 mg maintenance dose, a difference of $150 a month, or $1,800 across a year. Both are billed on the same flat structure. Captured 2026-08-05.

SkinnyRx charges $199 a month for semaglutide and $299 for tirzepatide at a 10 mg maintenance dose, a difference of $100 a month, or $1,200 across a year. Both are billed on the same flat structure. Captured 2026-08-05.

What the price gap buys

SURMOUNT-5 randomised adults with obesity to tirzepatide or semaglutide and reported a larger mean weight reduction on tirzepatide over 72 weeks. That is the strongest direct evidence available, and it is the reason the more expensive molecule commands its premium.

The caveats matter as much as the headline. A mean is not a prediction for one person, the distribution around it is wide, and the trial compared maximum tolerated doses rather than what any given patient will tolerate. Some people do better on semaglutide, and some cannot tolerate tirzepatide at the doses where its advantage appears.

Read as a purchasing decision, the trial says the more expensive molecule does more on average. It does not say it will do more for you.

Why tirzepatide costs more to make

Tirzepatide is a longer and more structurally complex peptide than semaglutide, it activates two incretin receptors rather than one, and its active ingredient sells at a premium to compounding pharmacies. The price gap is not only positioning; part of it is input cost.

That also means a tirzepatide programme has less room to discount. A tirzepatide price far below the market is more likely to be a promotional rate, a prepaid term or a starting dose than a genuinely cheaper supply chain.

If you are switching

Switching molecules restarts titration. You do not carry your tolerance across, because the dose ladders are not equivalent and the receptor targets differ. Budget for the titration months again rather than assuming you resume at an equivalent strength.

Ask three things before moving: whether the programme charges anything to switch, whether a prepaid term you have already paid transfers, and what dose your prescriber intends to start you at. The third is clinical and the first two are commercial, and programmes rarely volunteer any of them.

What this page assumes about you

That you are paying cash, that you will hold a maintenance dose rather than a starter dose, and that a difference of a few hundred dollars across a year is worth an hour of reading. If any of those is wrong, the ordering here changes.

Insurance is the biggest one. A covered prescription under a documented indication beats every cash route on this site, and establishing whether you qualify comes before comparing 16 cash prices spanning $215 to $597.

The bias we can see in our own data

We track what programmes publish, so programmes that publish well look better here than programmes that treat pricing as a sales conversation. That is a real bias and we would rather name it than pretend the dataset is neutral.

It cuts a defensible way — a programme unwilling to state a price before an intake has made a choice you should notice — but it is a bias, and 16 tracked programmes appear here with an explanation instead of a number because of it.

What we deliberately do not measure

Shipping reliability, response times, and whether the clinical oversight is any good. None is observable from outside without enrolling, and we did not enrol.

That absence is why there is no rating out of ten anywhere here. A single score would compress price, disclosure, service and clinical depth into one figure and hide the weighting — which is precisely the trick that makes comparison sites feel authoritative while telling you less than a table would.

The usable proxy is what a programme publishes before it has your money, and that is what every disclosure column here records.

The switching cost nobody prices

Moving programmes for a modest saving carries two costs a table cannot show: a supply gap while a new intake is reviewed, and a new prescriber restarting titration rather than continuing your dose.

The second is expensive. Eight to twelve weeks back through the ladder erases most of what a year's saving would have bought. Ask for dose continuation in writing before cancelling anything, and do not cancel until the new programme has shipped.

How semaglutide is priced at these programmes

Semaglutide runs $99 to $299 a month across the 14 programmes in our dataset that carry both molecules. The cheapest we verify is Mochi Health at $99 a month. Tirzepatide at the same programmes runs consistently higher, and the gap is structural rather than promotional.

Semaglutide is a shorter peptide with a longer manufacturing history and more compounding pharmacies equipped to produce it. Tirzepatide is longer, harder to synthesise, and its active ingredient sells at a premium. That difference in input cost is most of the price gap you see between the two columns.

Semaglutide titrates 0.25, 0.5, 1, 1.7 and 2.4 mg weekly, with four weeks at each step, so reaching a semaglutide maintenance dose takes roughly sixteen weeks against eight to twelve for tirzepatide. On a dose-scaled programme that longer ladder means more months at intermediate pricing, which partly offsets the lower headline figure.

What the head-to-head evidence supports

SURMOUNT-5 randomised adults with obesity to tirzepatide or semaglutide and reported a larger mean reduction in body weight on tirzepatide over 72 weeks. It is the strongest direct comparison between the two molecules and it is the reason tirzepatide sustains a premium in a market that otherwise competes hard on price.

The caveats matter. A mean is not a prediction for an individual and the distribution around it is wide; a substantial number of semaglutide participants did better than a substantial number of tirzepatide participants. Trial participants received structured support most telehealth programmes do not replicate. And the comparison was at maximum tolerated doses, which is a different question from what any given person will tolerate.

Semaglutide also carries the larger cardiovascular outcomes evidence base, which is a genuine advantage for some patients and is not captured by a weight-loss endpoint. Neither molecule is simply better than the other; they are differently evidenced.

Where semaglutide is the better buy

Semaglutide wins on three counts and it is worth stating them plainly on a site that leads with the other molecule. It is cheaper at every dual-molecule programme in our dataset. It has the larger cardiovascular outcomes evidence base, which matters for patients whose risk profile makes that endpoint relevant. And more compounding pharmacies produce it, which means supply disruption is less likely to interrupt a titration.

For someone paying cash whose goal is a sustainable course rather than a maximum result, the cheaper molecule they can afford for three years is frequently the better clinical bet than the more effective one they can afford for eight months. Discontinuation is the expensive outcome in this drug class, because the withdrawal evidence is consistent: weight returns when the drug stops, since it suppresses appetite while taken rather than resetting a set point.

Semaglutide is also the more forgiving starting point for people who are uncertain about tolerating an incretin at all. Starting cheaper, establishing tolerability and moving up later costs a second titration, but it risks less money against the possibility that neither molecule suits you.

Where tirzepatide justifies the premium

The head-to-head result is the whole case, and it is a strong one. On average, tirzepatide produced more weight reduction than semaglutide in a randomised comparison at maximum tolerated doses. For someone who has already completed a semaglutide titration and found the result insufficient, that evidence is directly relevant and the premium is defensible.

Tirzepatide also reaches maintenance faster. Its ladder runs 2.5 to 15 mg in 2.5 mg steps against semaglutide's 0.25 to 2.4 mg across five steps, which in practice means eight to twelve weeks to a maintenance dose against roughly sixteen. On a dose-scaled programme, the shorter ladder recovers part of the price difference.

What does not justify the premium is switching from an incomplete semaglutide course. If the dose was never optimised, the comparison being made is not between two molecules but between a finished course and an unfinished one.

Switching between the molecules

Moving from semaglutide to tirzepatide is not a dose conversion. There is no equivalence table between the two, and the standard approach is to restart tirzepatide at 2.5 mg and titrate from the bottom regardless of the semaglutide dose reached. That means paying for another titration period and tolerating another round of the gastrointestinal effects that cluster after each increase.

Priced honestly, a switch costs the titration months again. On a flat programme that is invisible because the price does not move by dose. On a dose-scaled one it can mean several months at intermediate pricing before reaching the dose you actually want.

The practical question is whether your current molecule has genuinely underperformed or whether the dose was never optimised. Switching from an under-titrated semaglutide course to a fresh tirzepatide titration frequently buys a result that a completed semaglutide titration would have produced more cheaply.